172 related articles for article (PubMed ID: 30690891)
21. Vascular endothelial growth factor-C and C-C chemokine receptor 7 in tumor cell-lymphatic cross-talk promote invasive phenotype.
Issa A; Le TX; Shoushtari AN; Shields JD; Swartz MA
Cancer Res; 2009 Jan; 69(1):349-57. PubMed ID: 19118020
[TBL] [Abstract][Full Text] [Related]
22. Tumor-targeted gene therapy with lipid nanoparticles inhibits tumor-associated adipocytes and remodels the immunosuppressive tumor microenvironment in triple-negative breast cancer.
Liu Y; Tiruthani K; Wang M; Zhou X; Qiu N; Xiong Y; Pecot CV; Liu R; Huang L
Nanoscale Horiz; 2021 Apr; 6(4):319-329. PubMed ID: 33587080
[TBL] [Abstract][Full Text] [Related]
23. Hypoxia preconditioning of mesenchymal stromal cells enhances PC3 cell lymphatic metastasis accompanied by VEGFR-3/CCR7 activation.
Huang X; Su K; Zhou L; Shen G; Dong Q; Lou Y; Zheng S
J Cell Biochem; 2013 Dec; 114(12):2834-41. PubMed ID: 23939705
[TBL] [Abstract][Full Text] [Related]
24. MicroRNA-200b targets protein kinase Cα and suppresses triple-negative breast cancer metastasis.
Humphries B; Wang Z; Oom AL; Fisher T; Tan D; Cui Y; Jiang Y; Yang C
Carcinogenesis; 2014 Oct; 35(10):2254-63. PubMed ID: 24925028
[TBL] [Abstract][Full Text] [Related]
25. MicroRNA 603 acts as a tumor suppressor and inhibits triple-negative breast cancer tumorigenesis by targeting elongation factor 2 kinase.
Bayraktar R; Pichler M; Kanlikilicer P; Ivan C; Bayraktar E; Kahraman N; Aslan B; Oguztuzun S; Ulasli M; Arslan A; Calin G; Lopez-Berestein G; Ozpolat B
Oncotarget; 2017 Feb; 8(7):11641-11658. PubMed ID: 28036267
[TBL] [Abstract][Full Text] [Related]
26. Local Blockade of Interleukin 10 and C-X-C Motif Chemokine Ligand 12 with Nano-Delivery Promotes Antitumor Response in Murine Cancers.
Shen L; Li J; Liu Q; Song W; Zhang X; Tiruthani K; Hu H; Das M; Goodwin TJ; Liu R; Huang L
ACS Nano; 2018 Oct; 12(10):9830-9841. PubMed ID: 30253648
[TBL] [Abstract][Full Text] [Related]
27. TAK1 mediates microenvironment-triggered autocrine signals and promotes triple-negative breast cancer lung metastasis.
Iriondo O; Liu Y; Lee G; Elhodaky M; Jimenez C; Li L; Lang J; Wang P; Yu M
Nat Commun; 2018 May; 9(1):1994. PubMed ID: 29777109
[TBL] [Abstract][Full Text] [Related]
28. Treating metastatic triple negative breast cancer with CD44/neuropilin dual molecular targets of multifunctional nanoparticles.
Liang DS; Zhang WJ; Wang AT; Su HT; Zhong HJ; Qi XR
Biomaterials; 2017 Aug; 137():23-36. PubMed ID: 28528300
[TBL] [Abstract][Full Text] [Related]
29. Silencing β3 Integrin by Targeted ECO/siRNA Nanoparticles Inhibits EMT and Metastasis of Triple-Negative Breast Cancer.
Parvani JG; Gujrati MD; Mack MA; Schiemann WP; Lu ZR
Cancer Res; 2015 Jun; 75(11):2316-2325. PubMed ID: 25858145
[TBL] [Abstract][Full Text] [Related]
30. Chemokine receptor CCR7 expression predicts poor outcome in uveal melanoma and relates to liver metastasis whereas expression of CXCR4 is not of clinical relevance.
van den Bosch T; Koopmans AE; Vaarwater J; van den Berg M; de Klein A; Verdijk RM
Invest Ophthalmol Vis Sci; 2013 Nov; 54(12):7354-61. PubMed ID: 24052640
[TBL] [Abstract][Full Text] [Related]
31. Effects of let-7a microRNA and C-C chemokine receptor type 7 expression on cellular function and prognosis in esophageal squamous cell carcinoma.
Yura M; Fukuda K; Matsuda S; Irino T; Nakamura R; Kawakubo H; Takeuchi H; Kitagawa Y
BMC Cancer; 2022 Oct; 22(1):1064. PubMed ID: 36243683
[TBL] [Abstract][Full Text] [Related]
32. Prognostic value of CC-chemokine receptor seven expression in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitor.
Xia Y; Liu L; Xiong Y; Bai Q; Wang J; Xi W; Qu Y; Xu J; Guo J
BMC Cancer; 2017 Jan; 17(1):70. PubMed ID: 28114889
[TBL] [Abstract][Full Text] [Related]
33. Tumor necrosis factor-α induces prostate cancer cell migration in lymphatic metastasis through CCR7 upregulation.
Maolake A; Izumi K; Natsagdorj A; Iwamoto H; Kadomoto S; Makino T; Naito R; Shigehara K; Kadono Y; Hiratsuka K; Wufuer G; Nastiuk KL; Mizokami A
Cancer Sci; 2018 May; 109(5):1524-1531. PubMed ID: 29575464
[TBL] [Abstract][Full Text] [Related]
34. EP300 knockdown reduces cancer stem cell phenotype, tumor growth and metastasis in triple negative breast cancer.
Ring A; Kaur P; Lang JE
BMC Cancer; 2020 Nov; 20(1):1076. PubMed ID: 33167919
[TBL] [Abstract][Full Text] [Related]
35. In vivo β-catenin attenuation by the integrin α5-targeting nano-delivery strategy suppresses triple negative breast cancer stemness and metastasis.
Li Y; Xiao Y; Lin HP; Reichel D; Bae Y; Lee EY; Jiang Y; Huang X; Yang C; Wang Z
Biomaterials; 2019 Jan; 188():160-172. PubMed ID: 30352320
[TBL] [Abstract][Full Text] [Related]
36. Unique cartilage matrix-associated protein inhibits the migratory and invasive potential of triple-negative breast cancer.
Lee SH; Lee YJ; Park SI; Kim JE
Biochem Biophys Res Commun; 2020 Oct; 530(4):680-685. PubMed ID: 32768190
[TBL] [Abstract][Full Text] [Related]
37. The potential use of lapatinib-loaded human serum albumin nanoparticles in the treatment of triple-negative breast cancer.
Wan X; Zheng X; Pang X; Zhang Z; Jing T; Xu W; Zhang Q
Int J Pharm; 2015 Apr; 484(1-2):16-28. PubMed ID: 25700543
[TBL] [Abstract][Full Text] [Related]
38. The CCL21/CCR7 pathway plays a key role in human colon cancer metastasis through regulation of matrix metalloproteinase-9.
Li J; Sun R; Tao K; Wang G
Dig Liver Dis; 2011 Jan; 43(1):40-7. PubMed ID: 20609636
[TBL] [Abstract][Full Text] [Related]
39. PKCλ/ι signaling promotes triple-negative breast cancer growth and metastasis.
Paul A; Gunewardena S; Stecklein SR; Saha B; Parelkar N; Danley M; Rajendran G; Home P; Ray S; Jokar I; Vielhauer GA; Jensen RA; Tawfik O; Paul S
Cell Death Differ; 2014 Sep; 21(9):1469-81. PubMed ID: 24786829
[TBL] [Abstract][Full Text] [Related]
40. Targeting the cancer-associated fibroblasts as a treatment in triple-negative breast cancer.
Takai K; Le A; Weaver VM; Werb Z
Oncotarget; 2016 Dec; 7(50):82889-82901. PubMed ID: 27756881
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
